Literature DB >> 16450141

First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent.

Yicheng Ni1, Dieter Huyghe, Kristin Verbeke, Peter A de Witte, Johan Nuyts, Luc Mortelmans, Feng Chen, Guy Marchal, Alfons M Verbruggen, Guy M Bormans.   

Abstract

PURPOSE: We have labelled hypericin, a polyphenolic polycyclic quinone found in St. John's wort (Hypericum perforatum), with( 123)I and evaluated mono-[(123)I]iodohypericin (MIH) as a potential necrosis-avid diagnostic tracer agent.
METHODS: MIH was prepared by an electrophilic radioiodination method. The new tracer agent was evaluated in animal models of liver infarction in the rat and heart infarction in the rabbit using single-photon emission computed tomography (SPECT), triphenyltetrazolium chloride (TTC) histochemical staining, serial sectional autoradiography and microscopy, and radioactivity counting techniques.
RESULTS: Using in vivo SPECT imaging, hepatic and cardiac infarctions were persistently visualised as well-defined hot spots over 48 h. Preferential uptake of the tracer agent in necrotic tissue was confirmed by perfect match of images from post-mortem TTC staining, autoradiography (ARX) and histology. Radioactivity concentration in infarcted tissues was over 10 times (liver; 3.51% ID/g in necrotic tissue vs 0.38% ID/g in normal tissue at 60 h p.i.) and over 6 times (myocardium; 0.36% ID/g in necrotic tissue vs 0.054% ID/g in normal tissue; ratios up to 18 for selected parts on ARX images) higher than in normal tissues.
CONCLUSION: The results suggest that hypericin derivatives may serve as powerful necrosis-avid diagnostic agents for assessment of tissue viability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16450141     DOI: 10.1007/s00259-005-0013-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  36 in total

1.  Occlusive myocardial infarction enhanced or not enhanced with necrosis-avid contrast agents at MR imaging.

Authors:  Yicheng Ni; Steven Dymarkowski; Feng Chen; Jan Bogaert; Guy Marchal
Journal:  Radiology       Date:  2002-11       Impact factor: 11.105

2.  Indium-111-monoclonal antimyosin antibody studies after the first year of heart transplantation. Identification of risk groups for developing rejection during long-term follow-up and clinical implications.

Authors:  M Ballester; D Obrador; I Carrió; J M Augé; C Moya; G Pons-Lladó; J M Caralps-Riera
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

3.  Noninvasive detection of human cardiac transplant rejection with indium-111 antimyosin (Fab) imaging.

Authors:  W Frist; T Yasuda; G Segall; B A Khaw; H W Strauss; H Gold; E Stinson; P Oyer; J Baldwin; M Billingham
Journal:  Circulation       Date:  1987-11       Impact factor: 29.690

Review 4.  The current role of infarct avid imaging.

Authors:  B A Khaw
Journal:  Semin Nucl Med       Date:  1999-07       Impact factor: 4.446

5.  Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy.

Authors:  B Chen; I Zupkó; P A de Witte
Journal:  Int J Oncol       Date:  2001-04       Impact factor: 5.650

6.  Localization and determination of infarct size by Gd-Mesoporphyrin enhanced MRI in dogs.

Authors:  P Herijgers; S K Laycock; Y Ni; G Marchal; J Bogaert; H Bosmans; C Petré; W Flameng
Journal:  Int J Card Imaging       Date:  1997-12

7.  Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings.

Authors:  Y Ni; G Marchal; J Yu; G Lukito; C Petré; M Wevers; A L Baert; W Ebert; C S Hilger; F K Maier
Journal:  Acad Radiol       Date:  1995-08       Impact factor: 3.173

8.  Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis.

Authors:  G W Dec; I Palacios; T Yasuda; J T Fallon; B A Khaw; H W Strauss; E Haber
Journal:  J Am Coll Cardiol       Date:  1990-07       Impact factor: 24.094

Review 9.  Non-invasive in vivo imaging of myocardial apoptosis and necrosis.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-14       Impact factor: 9.236

10.  High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction.

Authors:  R A Valdés Olmos; I Carrió; C A Hoefnagel; M Estorch; W W ten Bokkel Huinink; J López-Pousa; O Dalesio
Journal:  Nucl Med Commun       Date:  2002-09       Impact factor: 1.690

View more
  28 in total

Review 1.  An overview on development and application of an experimental platform for quantitative cardiac imaging research in rabbit models of myocardial infarction.

Authors:  Yuanbo Feng; Jan Bogaert; Raymond Oyen; Yicheng Ni
Journal:  Quant Imaging Med Surg       Date:  2014-10

Review 2.  Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.

Authors:  Yewei Liu; Ting Yin; Yuanbo Feng; Marlein Miranda Cona; Gang Huang; Jianjun Liu; Shaoli Song; Yansheng Jiang; Qian Xia; Johannes V Swinnen; Guy Bormans; Uwe Himmelreich; Raymond Oyen; Yicheng Ni
Journal:  Quant Imaging Med Surg       Date:  2015-10

3.  Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.

Authors:  Thierry Marysael; Matthias Bauwens; Yicheng Ni; Guy Bormans; Jef Rozenski; Peter de Witte
Journal:  Invest New Drugs       Date:  2011-12-21       Impact factor: 3.850

Review 4.  An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

Authors:  Marlein Miranda Cona; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  World J Methodol       Date:  2013-12-26

5.  Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.

Authors:  Thierry Marysael; Yicheng Ni; Evelyne Lerut; Peter de Witte
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-21       Impact factor: 4.553

6.  Effects of Glycosylation on Biodistribution and Imaging Quality of Necrotic Myocardium of Iodine-131-Labeled Sennidins.

Authors:  Ling Li; Dongjian Zhang; Shengwei Yang; Shaoli Song; Jindian Li; Qin Wang; Cong Wang; Yuanbo Feng; Yicheng Ni; Jian Zhang; Wei Liu; Zhiqi Yin
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

Review 7.  Biomarkers and molecular probes for cell death imaging and targeted therapeutics.

Authors:  Bryan A Smith; Bradley D Smith
Journal:  Bioconjug Chem       Date:  2012-09-26       Impact factor: 4.774

8.  Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis.

Authors:  Xiaojun Qi; Haibo Shao; Jian Zhang; Ziping Sun; Yicheng Ni; Ke Xu
Journal:  Radiol Med       Date:  2014-07-11       Impact factor: 3.469

9.  A single-dose toxicity study on non-radioactive iodinated hypericin for a targeted anticancer therapy in mice.

Authors:  Jun-jie Li; Marlein Miranda Cona; Yuan-bo Feng; Feng Chen; Guo-zhi Zhang; Xue-bin Fu; Uwe Himmelreich; Raymond Oyen; Alfons Verbruggen; Yi-cheng Ni
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 6.150

Review 10.  Small-animal SPECT and SPECT/CT: application in cardiovascular research.

Authors:  Reza Golestani; Chao Wu; René A Tio; Clark J Zeebregts; Artiom D Petrov; Freek J Beekman; Rudi A J O Dierckx; Hendrikus H Boersma; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.